What it meant to me!

 

DR NIA BRYANT, UNIVERSITY OF GLASGOW – prestige, equality and inspiration
BryantLister Fellowships have always been synonymous with prestige in the biomedical sciences and when my mentor, Professor Gwyn Gould, suggested that I apply for one of the first Lister Institute Research Prizes shortly after I moved to Glasgow to set up my own lab my immediate reaction was ‘that’s not for the likes of me’.  However, I followed his advice and put in an application and was delighted when I was invited for an interview with the Institute’s Scientific Advisory Committee.  At the time this consisted of Professors Richard Perham, Jean Beggs, Dame Louise Johnson, Simon Kroll, Birgitte Lane, Bob Michell, Linda Partridge and Alan Rickinson.  One of the first things that I noticed about this list (apart from the high calibre of scientists on it) was that it was 50% female.  This is in stark contrast to any other interview I have been involved in before or since, as either interviewee or interviewer.

I was, of course, delighted when I was awarded a Research Prize and excited to attend my first Fellows’ Meeting.  It was there that I first met Dame Bridget Ogilvie who took over as chair of the governing body the following year.  There can be no better role model for women in science than Bridget.  Her enthusiasm seems never ending and her story (which she recounted as part of her Special Lecture in 2011) is truly inspirational.

DR VICTORIA COWLING, UNIVERSITY OF DUNDEE – joining a scientific community
I started my lab in University of Dundee in December 2007.  Previously I had been a PhD student in Cancer Research UK, London and a postdoc in USA at Princeton University and Dartmouth College.  I was awarded the Lister Prize Fellowship in 2011.  I had applied for the fellowship because of the flexible funding that it provided.  Since receiving the fellowship, I have realised that that major benefit of being a Lister Fellow is being part of a community of pretty impressive scientists.  The fellowship meets one day a year in Cambridge for some informal presentations, discussion and dinner.  This meeting is invaluable for discussing our latest findings and receiving advice on future steps.  Every scientist in the Lister Fellowship works on a different area and therefore the perspective that other fellows have on our work often suggests directions and opportunities that I had not considered.  The Lister Fellows form a spectrum from new group leaders like myself to those that are retired, and therefore is also a great resource for career advice.

DR MICHAEL EDDLESTON, UNIVERSITY OF EDINBURGH – recognition of a ’Cinderella’ area of science and flexibility
I work in the ‘boutique’ (aka unfashionable) field of clinical toxicology, the specialty that cares for poisoned patients following self-harm or recreational use. There are just 16 consultant physicians in the UK and Ireland, sharing a national on-call rota covering 70 million people. Internationally, there are only two other full time clinical academics – both in Australia.

Most of my research has been done in rural Asia, in particular in the North Central Province of Sri Lanka where we have studied potential clinical and public health interventions to prevent deaths from self-poisoning with pesticides, plants, and medicines. We aim to lower global suicide rates by 20%, particularly by reducing deaths from pesticide poisoning. More recently I have combined this work with clinical, volunteer, and large animal studies of antidotes in Edinburgh.

Most of my funding has come from the Wellcome Trust (for Sri Lankan work) and from Scotland’s Chief Scientist Office (for UK based work). But all of this funding, except for my Scottish Senior Clinical Research fellowship, has been tied to particular studies. There have rarely been flexible funds available for pump priming work or for recruiting essential colleagues.

This is where the Lister research prize comes in. A colleague in Edinburgh, Andrew Jackson, had won one of the prizes in 2009. Somehow I heard about this – I can’t remember where or when now. It sounded extremely attractive – a national competition for £200,000 research grants, based on the quality of a project proposal but judged in the context of a whole research program. It offered a prestigious prize, a stamp of quality from a scientific advisory committee that knew nothing about my work, and fellowship with a group of highly successful scientists.

I applied for the prize in 2009 with a proposal for a novel area of work but failed to make the interview short list. Over the year, I worked on the application, gaining pilot data, before submitting an improved application in December 2010. This time I made the interview.

Flying down from Edinburgh, I arrived at the Royal Society a long time in advance of the interview. I read for a while and mentally practiced my talk before getting bored and standing up to walk about. Starting to talk with a woman waiting in the same room, I found out she was meeting Prof Borysiewicz whom I had last met in Cambridge 20 years before during my part II in pathology. When he arrived, she kindly introduced me to him as an ex-student who was waiting for a Lister interview. He pointed out that he was a former Lister fellow before asking about my research. Hearing about our Sri Lankan work, he said that had just returned from India where injuries are a major problem and where he had been told in admiring terms about our Sri Lankan work. This was encouraging to hear, leaving me in an excellent frame of mind just minutes before the interview. Perhaps this boost was why the interview went well….

The funds have proved invaluable, offering complete flexibility. The first thing I did was recruit a research projects coordinator – someone to keep an eye on the research finances and logistics and to help me with grant applications as I do the science. I also recruited a PhD student to run the research project with me in a collaborator’s lab. Already she has reproduced our large animal work and is now looking at the mechanisms of the neuromuscular junction failure that occurs after organophosphorus pesticide poisoning. A better understanding should allow us to identify antidotes to prevent this devastating complication of poisoning and save thousands of lives every year. Without the Lister Foundation’s prize, this work would have been much more difficult to drive through.

DR JOSEF KITTLER, UNIVERSITY COLLEGE LONDON developing a new research area
I started myKittler Large own lab at UCL with Career Development funding from the MRC. I am currently an MRC Senior Non-clinical Fellow focusing on the function and membrane trafficking of ion channels and organelles in healthy and diseased nerve cells.

I applied for a Lister award to develop a new area of research in my group to understand the molecular mechanisms important for regulating the membrane trafficking of organelles and in particular mitochondria within neuronal axons and dendrites. In particular we have been focusing on the key role played by the Miro family of mitochondrial GTPases for the delivery of mitochondria to activated synapses during neuronal activity. With the help of Lister funding we are focusing on how mitochondrial trafficking is regulated by neuronal activity and calcium signaling under healthy conditions and how disruption of these pathways contribute to neuronal pathology that underpins neurological disease. The Lister award has allowed me open up a completely new research direction in my group and importantly has also given me the freedom to think up and then test out new ideas. Moreover the flexibility of funding provided by a Lister award has facilitated the opportunity to recruit and interact with very clever, energetic and enthusiastic researchers to my lab. In addition to the award itself, the yearly Lister research meeting that brings together past and present fellows is a great opportunity to hear about an outstanding breadth of biomedical research covering a diverse array of topics in the life and medical sciences.

DR ROBIN MAY, UNIVERSITY OF BIRMINGHAM – ability to take risks and flexible funding
May LargeMy PhD research was undertaken in cell biology with Prof. Laura Machesky (now at the Beatson Institute, Glasgow), during which I investigated the role of the actin cytoskeleton in phagocytic cells. In 2001 I was awarded a Human Frontier Science Program (HFSP) fellowship to change fields and move to the Hubrecht Laboratory in The Netherlands to work with Ronald Plasterk (now a member of the Dutch Parliament). Here I investigated the mechanism that drives cell-to-cell transmission of double-stranded RNA6 before developing an independent line of research, modeling infectious disease processes in C. elegans.

In 2005 I was awarded an RCUK Fellowship to build on this work as an independent Principal Investigator in the School of Biosciences, University of Birmingham, where I am now Reader in Infectious Disease.

I was awarded my Lister Fellowship in 2010, for a proposal to study the fatal fungal pathogen Cryptococcus neoformans using both in vitro cellular models and the zebrafish, Danio rerio. The award transformed our overall research programme. Most importantly, aspects of the proposal had previously been rejected by other funding bodies for being “too risky” – the Lister’s investment provided us with evidence that other funders had confidence in the strategy and enabled us to generate proof-of-principle data that subsequently encouraged research council investment in this approach.

By far the most exceptional aspect of the Lister Fellowship is the flexibility of the funds.  Over the last two years this has allowed us to bridge salaries, buy critical small items of equipment and, in general, to maintain a rapid pace of research by ‘filling in gaps’ between other grants.  In short, it is probably the single most important award I’ve received in my career thus far, so for anyone thinking about applying, my advice is “Don’t hesitate!”.

DR NINA BALTHASAR, UNIVERSITY OF BRISTOL- flexible funding aids creativity
Nina Balthasar 3 snipFollowing my PhD. at the National Institute for Medical Research in London, a Wellcome Trust Prize Travelling Fellowship allowed me to join Dr.Brad Lowell’s lab at Harvard Medical School in Boston, USA. Here, I became very interested in how the CNS senses, integrates and adjusts metabolic state and we investigated the function of hormone receptors in specific neuronal sub-populations in the hypothalamic regulation of energy homeostasis using state-of-the-art conditional genetically modified models of human disease. I spent a very productive and inspiring time in the Lowell lab, learning and applying cutting-edge science without significant financial boundaries. These 5 years of unconstrained creativity led to publications in Neuron and Cell.

I moved back to the UK in January 2006 and was fortunate to secure independent fellowship funding from the British Heart Foundation as well as establishing myself in a permanent position at the University of Bristol on the back of an RCUK Academic Research Fellowship. Unfortunately, neither of these fellowships came with sufficient funds to allow me to continue the state-of-the-art technologies I had applied in Boston. I was now interested in how hypothalamic glucose-sensing goes wrong in obesity and also how obesity-induced hypertension arises, particularly in relation to novel genes highlighted by Genome-Wide Association Studies. There were (and still are!) many unanswered questions around CNS neurogenetic pathways regulating metabolic and cardiovascular states, most of which can only be fully addressed using systems-level analysis of physiology; without funds to generate and analyse new genetically modified models, my research was in danger of being curtailed.

It was the Lister Institute for Preventive Medicine Prize which allowed me to perform research at an internationally competitive standard. Having a flexible £200,000 at my disposal enabled the creativity I had enjoyed at Harvard, allowing me to design a focused but adaptable research program.

With the Lister Prize I have generated new genetically modified models, retained and employed key staff between grants and delved into new (expensive but very exciting) avenues of next generation transcriptome sequencing. Critically, the Lister Prize further allowed my lab to keep running whilst I was away on maternity leave. The outcome of all this is not just continued publication in respected journals, but also preliminary data leading to BBSRC project grant funding, an ability to maintain international collaborations and last but not least progression within the University.  A recent application for EC funds reminded me how refreshing and easy the Lister Institute’s ‘admin light’ approach to grant application, reporting and management is; again, it allows full focus on research.

Sadly, my time as a ‘current Lister Fellow’ is over, but because of the Lister Prize I am ideally equipped with publications and preliminary data to apply for a Senior Fellowships or the like. In addition, the annual Lister meetings make sure that all current and former Lister fellows stay in touch as an invaluable research community.